vs
Side-by-side financial comparison of T Stamp Inc (IDAI) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.
T Stamp Inc is the larger business by last-quarter revenue ($908.9K vs $820.2K, roughly 1.1× InMed Pharmaceuticals Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -279.9%, a 32.6% gap on every dollar of revenue. On growth, InMed Pharmaceuticals Inc. posted the faster year-over-year revenue change (-26.2% vs -39.3%). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -16.4%).
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
IDAI vs INM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $908.9K | $820.2K |
| Net Profit | $-2.5M | $-2.0M |
| Gross Margin | — | 22.5% |
| Operating Margin | -224.9% | -247.3% |
| Net Margin | -279.9% | -247.3% |
| Revenue YoY | -39.3% | -26.2% |
| Net Profit YoY | 57.7% | 21.2% |
| EPS (diluted) | $-0.37 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $908.9K | $820.2K | ||
| Q3 25 | $872.5K | $1.1M | ||
| Q2 25 | $812.7K | $1.3M | ||
| Q1 25 | $545.5K | $1.3M | ||
| Q4 24 | $1.5M | $1.1M | ||
| Q3 24 | $511.1K | $1.3M | ||
| Q2 24 | $500.4K | $1.3M | ||
| Q1 24 | $573.7K | $1.2M |
| Q4 25 | $-2.5M | $-2.0M | ||
| Q3 25 | $-1.9M | $-1.7M | ||
| Q2 25 | $-1.7M | $-1.8M | ||
| Q1 25 | $-2.2M | $-2.1M | ||
| Q4 24 | $-6.0M | $-2.6M | ||
| Q3 24 | $-1.3M | $-1.7M | ||
| Q2 24 | $-2.6M | $-1.9M | ||
| Q1 24 | $-2.7M | $-1.7M |
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 36.0% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | — | 13.9% | ||
| Q4 24 | — | 41.5% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 36.3% | ||
| Q1 24 | — | 24.7% |
| Q4 25 | -224.9% | -247.3% | ||
| Q3 25 | -203.0% | -154.2% | ||
| Q2 25 | -207.0% | -137.1% | ||
| Q1 25 | -396.5% | -168.1% | ||
| Q4 24 | -81.2% | -231.6% | ||
| Q3 24 | -523.7% | -132.7% | ||
| Q2 24 | -524.7% | -150.5% | ||
| Q1 24 | -496.7% | -146.9% |
| Q4 25 | -279.9% | -247.3% | ||
| Q3 25 | -219.1% | -154.2% | ||
| Q2 25 | -210.7% | -137.1% | ||
| Q1 25 | -395.5% | -168.1% | ||
| Q4 24 | -401.5% | -231.6% | ||
| Q3 24 | -245.7% | -132.7% | ||
| Q2 24 | -519.3% | -151.0% | ||
| Q1 24 | -466.9% | -146.9% |
| Q4 25 | $-0.37 | $-0.51 | ||
| Q3 25 | $-0.72 | $-0.44 | ||
| Q2 25 | $-0.69 | $-0.07 | ||
| Q1 25 | $-0.89 | $-1.94 | ||
| Q4 24 | $-3.14 | $-3.64 | ||
| Q3 24 | $-1.06 | $-2.71 | ||
| Q2 24 | $-3.19 | $2.39 | ||
| Q1 24 | $-3.97 | $-3.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.7M | $9.6M |
| Total Assets | $11.2M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | $7.0M | ||
| Q3 25 | $5.4M | $9.4M | ||
| Q2 25 | $292.1K | $11.1M | ||
| Q1 25 | $1.1M | $4.7M | ||
| Q4 24 | $2.8M | $3.5M | ||
| Q3 24 | $598.0K | $5.6M | ||
| Q2 24 | $659.5K | $6.6M | ||
| Q1 24 | $816.7K | — |
| Q4 25 | $8.7M | $9.6M | ||
| Q3 25 | $6.1M | $11.6M | ||
| Q2 25 | $2.4M | $13.4M | ||
| Q1 25 | $4.1M | $7.0M | ||
| Q4 24 | $3.0M | $6.2M | ||
| Q3 24 | $5.4M | $8.4M | ||
| Q2 24 | $750.4K | $9.2M | ||
| Q1 24 | $1.4M | $11.1M |
| Q4 25 | $11.2M | $11.2M | ||
| Q3 25 | $11.2M | $13.4M | ||
| Q2 25 | $5.7M | $15.6M | ||
| Q1 25 | $6.6M | $9.3M | ||
| Q4 24 | $8.6M | $8.5M | ||
| Q3 24 | $10.6M | $10.5M | ||
| Q2 24 | $5.2M | $11.8M | ||
| Q1 24 | $5.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-2.4M |
| Free Cash FlowOCF − Capex | $2.0M | — |
| FCF MarginFCF / Revenue | 215.4% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-2.4M | ||
| Q3 25 | $-4.0M | $-1.6M | ||
| Q2 25 | $-2.1M | $-1.8M | ||
| Q1 25 | $-1.5M | $-1.7M | ||
| Q4 24 | $-2.7M | $-2.5M | ||
| Q3 24 | $-2.4M | $-1.8M | ||
| Q2 24 | $-1.6M | $-1.0M | ||
| Q1 24 | $-2.2M | $-1.9M |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | $-1.9M |
| Q4 25 | 215.4% | — | ||
| Q3 25 | -459.6% | — | ||
| Q2 25 | -258.6% | — | ||
| Q1 25 | -289.2% | — | ||
| Q4 24 | -182.9% | — | ||
| Q3 24 | -475.4% | — | ||
| Q2 24 | -320.9% | — | ||
| Q1 24 | -376.6% | -165.0% |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.5% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
